Fundraising Fox
Nava Therapeutics
Founded 2022 · 37 employees on LinkedIn · 3 known investors
Find your way into Nava Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
91 people can intro you to Curtis
Ask Jeff Marrazzo to introduce you to Curtis Dobrowolski
You →Jeff · together at Nava Therapeutics →Curtis
Sign up to find every way you can get introduced to Nava Therapeutics
- Your email: who you already know at Nava Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Nava Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Nava develops lipid nanoparticles (LNPs) designed to deliver RNA therapeutics to specific organs and cellular targets for genetic medicine applications. The company focuses on addressing unmet medical needs across a range of RNA therapeutic treatments.
Founders & leadership
Nava Therapeutics was founded in 2022 by Curtis Dobrowolski.
CD
Curtis DobrowolskiCo-FounderCurtis Dobrowolski holds a PhD in molecular virology from Case Western Reserve University School of Medicine and has worked as a researcher in higher education with expertise in cell biology and molecular biology.
Investors · 3
Related companies · 8
OrnaOrna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications. The company leverages proprietary drug development expertise in oRNA and LNP technology platforms.
Abeona TherapeuticsAbeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases with high unmet need, including its approved product ZEVASKYN and its lead PSMA-targeted T cell therapy ABO-701 for advanced prostate cancer. It uses ex vivo gene therapy, viral vector, and synthetic immune receptor T cell (SIR-T) technologies to serve patients with genetic diseases and solid tumors.
Navega TherapeuticsNavega Therapeutics develops gene therapies using zinc-finger and CRISPR-based epigenome regulation to control gene expression. The company works in the biotech and gene therapy space.
Jnana TherapeuticsJnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins. The platform uses proprietary reactive affinity probes and high-throughput screening to accelerate drug discovery across challenging target classes including transporters, transcription factors, and GPCRs.
Averna TherapeuticsAverna Therapeutics is a biotechnology company developing therapeutics. The page is a team bio profiling its CEO and board member.
Neurona TherapeuticsNeurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system. Founded by neuroscientists and stem cell researchers from UC San Francisco, it operates a regenerative medicine discovery platform and manufactures neuronal, glial, and gene-edited cell therapy candidates in its own cGMP facility.
Sionna TherapeuticsSionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.
ロゴマーク：AIRNAAIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA. The company targets diseases where the underlying genetic mechanism is well-established and difficult to address with existing therapeutic approaches.
Companies working in the same space as Nava Therapeutics.
Frequently asked questions
- What does Nava Therapeutics do?
- Nava develops lipid nanoparticles (LNPs) designed to deliver RNA therapeutics to specific organs and cellular targets for genetic medicine applications. The company focuses on addressing unmet medical needs across a range of RNA therapeutic treatments.
- Who founded Nava Therapeutics?
- Nava Therapeutics was founded by Curtis Dobrowolski in 2022.
- Who are Nava Therapeutics's investors?
- Nava Therapeutics's investors include Andreessen Horowitz, F-Prime Capital, GV (Google Ventures).